Liraglutide Is an Efficacious Treatment for Type 2 
Placebo. The HbA1c scores (a measure of long-term blood-sugar control) of patients in the study was initially measured and ranged from 7% to 11%. After a total of 52 weeks of treatment patients who received 1.8 milligrams of Liraglutide showed a 1.14% drop in their HbA1c scores. HbA1c scores dropped 0.84% in patients who received 1.2 milligram doses of Liraglutide. In comparison, the patients who were dosed with Amaryl showed a less significant drop of 0.51% in their HbA1c scores. Additionally, an encouraging 51% of patients who received the 1.8 milligram doses of Liraglutide reached a target HbA1c level of less than 7.0%, which is the American Diabetes Association target HbA1c level. A healthy 43% of patients who were dosed with 1.2 milligrams of Liraglutide reached the ADA target HbA1c level. Only 28% of patients who were dosed with Amaryl reached the ADA target HbA1c level. Another enlightening result from this study was that the patients who received Liraglutide actually lost weight, while many of the patients treated with Amaryl gained weight. The patient weight loss, which was recorded over the first 16 weeks of the study, was also documented as being maintained by patients at the one-year mark of this trial. One more bonus of Liraglutide was that patients who were dosed with this phenomenal drug had a reduced blood pressure, even greater than the reduction that Amaryl elicited. Type 2 diabetes mellitus affects approximately 24 million people in the United States, and it is the leading cause of kidney failure and blindness. Shockingly, type 2 diabetes is also associated with almost a quadrupling of the risk of death for patients from cardiovascular causes. With the numbers of people with type 2 diabetes expected to increase worldwide due to the obesity epidemic, innovative, safe and efficacious treatments are greatly needed. For researchers, practitioners and patients concerned with the possibility of pancreatitis amongst those people dosed with Liraglutide long-term, the incidence of this condition has been minimal. In both the phase 2 and phase 3 trials of Liraglutide, there were seven total cases of pancreatitis reported out of 4, 257 patients treated with Liraglutide. Prescribers and patients are advised to note persistent or severe nausea and vomiting, as these symptoms could potentially be early manifestations of pancreatitis. The advent of tolerable and effectual medications to treat patients with type 2 diabetes is a must for the current generation of patients worldwide who are struggling with obesity and glycemic control issues. Liraglutide is an anti-diabetes medication that shows promise not only for the present, but also for the future.
2012 All rights reserved by Yes Pharma Ltd.
Source: http://yespharma.com/uploads/files/Liraglutide.pdf
A 65-year-old male patient presented with progressive shortness of breath over the past 3 months, recently even at rest. He neither complained about fever nor about chest pain. The laboratory findings were normal with only a slight increase in leuco-cytes. A significant restrictive ventilation disorder was noted on plethysmography. His past medical history included three vessel coronary artery dis
2ND YEAR RESEARCH ELECTIVE RESIDENT’S JOURNAL Smoking Cessation Knowledge and Clinical Cessation Techniques Among Medicine Residents Lisa Hope A. Purpose To study the knowledge and confidence level of smoking cessation techniques among medicine residents, and to correlate this information with clinical behavior in the AIM clinic. Smoking-related disease is the leading cause o